RIPK1 and systemic inflammatory response syndrome: Furthermore, RIPK1 is the cellular target of a new series of type III kinase inhibitors, of which the highly potent and selective compound is the N-benzyl-N-hydroxy-2,2-dimethylbutanamide (RIPA-56), that shows an impressive and efficient protection of mice from TNFα-induced mortality and multiorgan damage in the systemic Inflammatory Response Syndrome (SIRS) disease [136].